Cargando…

Determination of the most appropriate method for extrapolating overall survival data from a placebo-controlled clinical trial of lenvatinib for progressive, radioiodine-refractory differentiated thyroid cancer

BACKGROUND: Cost-effectiveness models for the treatment of long-term conditions often require information on survival beyond the period of available data. OBJECTIVES: This paper aims to identify a robust and reliable method for the extrapolation of overall survival (OS) in patients with radioiodine-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tremblay, Gabriel, Livings, Christopher, Crowe, Lydia, Kapetanakis, Venediktos, Briggs, Andrew
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Methodology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4934460/ https://www.ncbi.nlm.nih.gov/pubmed/27418847 http://dx.doi.org/10.2147/CEOR.S107498

Ejemplares similares

Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial
por: Kiyota, Naomi, et al.
Publicado: (2017)

Use of multikinase inhibitors/lenvatinib concomitant with radioiodine for the treatment of radioiodine refractory differentiated thyroid cancer
por: Herranz, Urbano Anido
Publicado: (2022)

Lenvatinib in Advanced Radioiodine-Refractory Thyroid Cancer - A Retrospective Analysis of the Swiss Lenvatinib Named Patient Program
por: Balmelli, Catharina, et al.
Publicado: (2018)

A Criterion-based Approach for the Systematic and Transparent Extrapolation of Clinical Trial Survival Data
por: Tremblay, Gabriel, et al.
Publicado: (2015)

Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer
por: Lorusso, Loredana, et al.
Publicado: (2016)

Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer: Treatment Optimization for Maximum Clinical Benefit
por: Wirth, Lori J, et al.
Publicado: (2022)

Impact of baseline tumor burden on overall survival in patients with radioiodine‐refractory differentiated thyroid cancer treated with lenvatinib in the SELECT global phase 3 trial
por: Kiyota, Naomi, et al.
Publicado: (2022)

Lenvatinib-Associated Cervical Artery Dissections in a Patient with Radioiodine-Refractory Metastatic Papillary Thyroid Carcinoma
por: Groden, Phillip J., et al.
Publicado: (2018)

Exposure–response analysis and simulation of lenvatinib safety and efficacy in patients with radioiodine-refractory differentiated thyroid cancer
por: Hayato, Seiichi, et al.
Publicado: (2018)

(18)F-FDG-PET/CT in Patients with Advanced, Radioiodine Refractory Thyroid Cancer Treated with Lenvatinib
por: Ahmaddy, Freba, et al.
Publicado: (2021)

A Randomized, Phase III Study of Lenvatinib in Chinese Patients with Radioiodine-Refractory Differentiated Thyroid Cancer
por: Zheng, Xiangqian, et al.
Publicado: (2021)

Clinical use of lenvatinib in patients with previous renal and/or hepatic impairment and radioiodine‐refractory differentiated thyroid cancer
por: Martínez‐Trufero, Javier
Publicado: (2022)

Use of multikinase inhibitors/lenvatinib concomitant with locoregional therapies for the treatment of radioiodine‐refractory differentiated thyroid cancer
por: Berciano‐Guerrero, Miguel‐Ángel
Publicado: (2022)

Use of lenvatinib in the treatment of radioiodine-refractory differentiated thyroid cancer: a multidisciplinary perspective for daily practice
por: Capdevila, Jaume, et al.
Publicado: (2023)

Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine‐refractory differentiated thyroid cancer
por: Kiyota, Naomi, et al.
Publicado: (2015)

Low Dose of Lenvatinib Treatment for Patients of Radioiodine-Refractory Differentiated Thyroid Carcinoma – A Real-World Experience
por: Jiang, He-Jiun, et al.
Publicado: (2021)

Correlation of Performance Status and Neutrophil-Lymphocyte Ratio with Efficacy in Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Lenvatinib
por: Taylor, Matthew H., et al.
Publicado: (2021)

Exploratory Analysis to Predict Optimal Tumor Burden for Starting Lenvatinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer
por: Suzuki, Chiaki, et al.
Publicado: (2021)

Use of multikinase inhibitors/lenvatinib in patients with high cardiovascular risk/vasculopathy and radioiodine refractory‐differentiated thyroid cancer
por: Jimenez‐Fonseca, Paula
Publicado: (2022)

Planned drug holidays during treatment with lenvatinib for radioiodine-refractory differentiated thyroid cancer: a retrospective study
por: Matsuyama, Chihiro, et al.
Publicado: (2023)

Reinducing Radioiodine-Sensitivity in Radioiodine-Refractory Thyroid Cancer Using Lenvatinib (RESET): Study Protocol for a Single-Center, Open Label Phase II Trial
por: Dotinga, Maaike, et al.
Publicado: (2022)

Clinical efficacy of lenvatinib for the treatment of radioiodine‐refractory thyroid carcinoma: A systematic review and meta‐analysis of clinical trials
por: Yan, Zhipeng, et al.
Publicado: (2021)

A Randomized Study of Lenvatinib 18 mg vs 24 mg in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer
por: Brose, Marcia S, et al.
Publicado: (2021)

Bayesian hierarchical model-based network meta-analysis to overcome survival extrapolation challenges caused by data immaturity
por: Heeg, Bart, et al.
Publicado: (2023)

Real-World Data for Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer (RELEVANT): A Retrospective Multicentric Analysis of Clinical Practice in Austria
por: Rendl, G., et al.
Publicado: (2020)

INES: Interactive tool for construction and extrapolation of partitioned survival models
por: Gimeno-Ballester, Vicente, et al.
Publicado: (2023)

Radioiodine refractoriness score: A multivariable prediction model for postoperative radioiodine‐refractory differentiated thyroid carcinomas
por: Li, Genpeng, et al.
Publicado: (2018)

Sensitivity analysis for random measurement error using regression calibration and simulation-extrapolation
por: Nab, Linda, et al.
Publicado: (2021)

A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine‐refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment
por: Cabanillas, Maria E., et al.
Publicado: (2015)

Lenvatinib complementary with radioiodine therapy for patients with advanced differentiated thyroid carcinoma: case reports and literature review
por: Sheu, Nai-Wei, et al.
Publicado: (2019)

Which is the Most Appropriate Disconnection Surgery for Refractory Epilepsy in Childhood?
por: Kishima, Haruhiko, et al.
Publicado: (2013)

Feasibility of Apatinib in Radioiodine-Refractory Differentiated Thyroid Carcinoma
por: Du, Wei, et al.
Publicado: (2022)

Molecular Theranostics in Radioiodine-Refractory Differentiated Thyroid Cancer
por: Petranović Ovčariček, Petra, et al.
Publicado: (2023)

Estimating Lifetime Benefits Associated with Immuno-Oncology Therapies: Challenges and Approaches for Overall Survival Extrapolations
por: Ouwens, Mario J. N. M., et al.
Publicado: (2019)

Linear Low-Dose Extrapolation for Noncancer Responses Is Not Generally Appropriate
por: Rhomberg, Lorenz R.
Publicado: (2009)

Whole blood viscosity extrapolation formula: Note on appropriateness of units
por: Nwose, Ezekiel Uba, et al.
Publicado: (2011)

Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer
por: Worden, Francis, et al.
Publicado: (2015)

Radioiodine Refractory Follicular Thyroid Cancer and Surgery for Cervical Relapse
por: Chiapponi, Costanza, et al.
Publicado: (2021)

New approaches for patients with advanced radioiodine-refractory thyroid cancer
por: Pitoia, Fabián, et al.
Publicado: (2022)

Management of Progressive Radioiodine-Refractory Thyroid Carcinoma: Current Perspective
por: Nervo, Alice, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_b3nuipohtr39974hn8f0cdiiju